Impact of regulatory issues on drug development for the CNS

被引：0
|
作者：
Kuruma, I
机构：
来源：
PRECLINICAL AND CLINICAL STRATEGIES FOR THE TREATMENT OF NEURODEGENERATIVE, CEREBROVASCULAR AND MENTAL DISORDERS | 1996年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：281 / 282
页数：2
相关论文
共 50 条
  • [21] Phosphodiesterases in the CNS: targets for drug development
    Menniti, Frank S.
    Faraci, W. Stephen
    Schmidt, Christopher J.
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) : 660 - 670
  • [22] Imaging Biomarkers in CNS Drug Development
    Tauscher, J.
    Schwarz, A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 34 - 35
  • [23] The utility of biomarkers in CNS drug development
    Palmer, Alan M.
    DRUG DISCOVERY TODAY, 2014, 19 (03) : 201 - 203
  • [24] FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes
    Kesselheim, A. S.
    Darrow, J. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (01) : 29 - 36
  • [25] Erratum to “Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development”
    Elizabeth Yen
    Jonathan M. Davis
    Christopher-Paul Milne
    Therapeutic Innovation & Regulatory Science, 2019, 53 : 797 - 797
  • [26] Overall impact of the regulatory requirements for genotoxic impurities on the drug development process
    Giordani, Antonio
    Kobel, Werner
    Gally, Hans Ulrich
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 43 (1-2) : 1 - 15
  • [27] CURRENT ISSUES IN REGULATORY REQUIREMENTS OF DRUG STABILITY
    CHOW, SC
    PONG, AP
    JOURNAL OF FOOD AND DRUG ANALYSIS, 1995, 3 (02) : 75 - 85
  • [28] Trade, development, and regulatory issues in food
    Ramaswamy, Sunder
    Viswanathan, Brinda
    FOOD AND NUTRITION BULLETIN, 2007, 28 (01) : S123 - S140
  • [29] REGULATORY ISSUES IN THE DEVELOPMENT AND FUTURE OF THE AICD
    ACHARYA, A
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1991, 14 (05): : 880 - 882
  • [30] Regulatory issues related to marker development
    Taube, SE
    Freiberg, GP
    UROLOGIC ONCOLOGY, 2000, 5 (05): : 214 - 216
12345